Open access
Oct 2026
Prospective Study of Efficacy, Safety, and Predictors of Response to Deucravacitinib in Chinese Patients with Moderate-to-Severe Plaque Psoriasis
In this real-world study, deucravacitinib was associated with significant clinical improvement over 12 weeks and had a favorable safety profile in Chinese patients with moderate-to-severe psoriasis, including improvement in difficult-to-treat anatomical regions.
Can-Bin Dong, Yi-Lun Wang, Jia-Zheng Sun et al.
· Psoriasis · 0 citations